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Dyslipidemia is a common ﬁnding in patients with thyroid disease, explained by the adverse eﬀects of thyroid hormones in almost
all steps of lipid metabolism. Not only overt but also subclinical hypo- and hyperthyroidism, through diﬀerent mechanisms,
are associated with lipid alterations, mainly concerning total and LDL cholesterol and less often HDL cholesterol, triglycerides,
lipoprotein (a), apolipoprotein A1, and apolipoprotein B. In addition to quantitative, qualitative alterations of lipids have been
also reported, including atherogenic and oxidized LDL and HDL particles. In thyroid disease, dyslipidemia coexists with various
metabolic abnormalities and induce insulin resistance and oxidative stress via a vice-vicious cycle. The above associations in
combination with the thyroid hormone induced hemodynamic alterations, might explain the increased risk of coronary artery
disease, cerebral ischemia risk, and angina pectoris in older, and possibly ischemic stroke in younger patients with overt or
subclinical hyperthyroidism.
1.Introduction
Thyroid disease, namely hypothyroidism and hyperthyroid-
ism, constitutes the most common endocrine abnormality
in recent years, diagnosed either in subclinical or clinical
form. According to the 6-year duration NHANES III Study,
the prevalence of hypothyroidism was 4.6% (0.3% clinical
and 4.3% subclinical) and of hyperthyroidism 1.3% (0.5%
clinical and 0.7% subclinical), in population aged at least 12
years, showing an age and sex dependence [1].
Thyroid disease is associated with various metabolic ab-
normalities, due to the eﬀects of thyroid hormones on nearly
all major metabolic pathways. Thyroid hormones regulate
the basal energy expenditure through their eﬀect on protein,
carbohydrate, and lipid metabolism. This might be a direct
eﬀectoranindirecteﬀectbymodiﬁcationofotherregulatory
hormones such as insulin or catecholamines [2]. Dyslipi-
demia is a common metabolic abnormality in patients with
thyroid disease, either in the overt or subclinical forms of the
disease, and constitutes the end result of the eﬀect of thyroid
hormones in all aspects of lipid metabolism leading to var-
ious quantitative and/or qualitative changes of triglycerides,
phospholipids, cholesterol, and other lipoproteins [3].
In thyroid disease, dyslipidemia and the coexisting met-
abolic abnormalities, in combination with the thyroid hor-
mone-induced hemodynamic alterations, explain the high
risk for cardiovascular disease [4–7].
2. Effects of Thyroid Hormones on
LipidMetabolism
Thyroid hormones inﬂuence all aspects of lipid metabolism
including synthesis, mobilization, and degradation [3]. Thy-
roid hormones stimulate cholesterol synthesis by inducing
3-hydroxy-3-methyl-glutaryl coenzyme A reductase in the
liver [8]. Thyroid hormones aﬀect lipoprotein lipase activity
and thus, the hydrolysis of triglycerides into very-low,
density lipoprotein (VLDL) and chylomicrons into fatty2 Journal of Lipids
Table 1: Changes in enzyme activities, transfer proteins, and recep-
tors involved in lipid metabolism induced by thyroid hormones.
Enzymes, transfer proteins, and liver
receptors Thyroid hormone eﬀect
3-hydroxy-3-methyl-glutaryl coenzyme
Ar e d u c t a s e
↑
Adipose lipoprotein lipase Usually normal (may be
↓ in hypothyroidism)
Hepatic lipase ↑
C h o l e s t e r y le s t e rt r a n s f e rp r o t e i n ↑
ATP-binding cassette transporter A1 ↓
Acetyl-CoA carboxylase 1 ↑
Carnitine palmitoyltransferase Ia ↑
7alpha-hydroxylase ↓
LDL receptor ↑
acids and glycerol [3]. In hypothyroidism, lipoprotein lipase
activity in the adipose tissue has been found normal or
decreased, in addition to decreased hepatic lipase activity
resulting in normal or high levels of triglycerides [9–11].
In hyperthyroidism, although lipoprotein lipase activity is
usuallynormal[10,12],anincreasedliverfattyacidsynthesis
and oxidation is observed due to enhanced acetyl-CoA car-
boxylase 1 and carnitine palmitoyltransferase Ia expression
leading to increased VLDL biosynthesis [13, 14]. Thyroid
hormonesaﬀectcholesterylestertransferproteinandhepatic
lipase activity, which are increased in hyperthyroidism and
decreased in hypothyroidism, with consequent changes not
onlyintotalhigh-densitylipoprotein(HDL)butalsoinHDL
subfraction levels [12, 15]. Furthermore, thyroid hormones,
by binding to the thyroid hormone receptor, inhibit through
a competitive action the liver X-receptor-mediated ATP-
binding cassette transporter A1 gene expression, resulting
in decreased HDL levels in patients with hyperthyroidism
and increased in hypothyroidism [14, 16]. Experimental
evidence suggests that thyroid hormones might also aﬀect
cholesterol-7alpha-hydroxylase in liver [17, 18]. Thyroid
hormones, especially triiodothyronine (T3), induce low-
density lipoprotein (LDL) receptor gene expression in the
liver, enhancing LDL clearance and explaining the decreased
or increased LDL levels observed in hyperthyroidism and
hypothyroidism, respectively [3]. Thyroid receptors seem to
mediatetheeﬀectsofthyroidhormonesonlipidmetabolism,
and more speciﬁcally alpha 1 receptors control the lipogen-
esis in white adipose tissue, and β receptors regulate the ac-
tivity of lipogenic and lipolytic enzymes in the liver [3, 14].
The changes induced by thyroid hormones in enzyme ac-
tivities, transfer proteins, and liver receptors involved in lipid
metabolism are summarized in Table 1.
Dyslipidemia is also due to the coexisting metabolic ab-
normalities in thyroid disease including oxidative stress and
insulin resistance, which induce further or aggravate the
existed dyslipidemia, via a vice-vicious cycle [19–28].
The lipid abnormalities observed in thyroid disorders are
presented in Table 2.
3. LipidAbnormalities inHypothyroidism
Dyslipidemia is a common ﬁnding in patients with clinical
hypothyroidism, consisting of high levels of total and LDL
cholesterol [3, 28–30]. Data regarding triglycerides, lipopro-
tein (a) (Lp(a)), HDL, apolipoprotein B (apoB), and apol-
ipoprotein A1 (apoA1) components are scarce, reporting ei-
ther higher or similar to euthyroid subjects levels [3, 22, 28–
34]( Table 2). Qualitative changes of various lipid compo-
nents have also been reported in clinical hypothyroidism,
such as the enhanced LDL oxidation, reﬂected on the in-
creased levels of markers of lipid peroxidation, such as MDA
and thiobarbituric acid-reactive substances [19–24, 35].
The observed abnormalities in total and LDL cholesterol
areassociatedwiththechangesinthethyroidhormonelevels
in hypothyroidism, as they are signiﬁcantly improved after
thyroxine replacement treatment [29, 30, 36–40]. However,
triglycerides, apoB, apoA1, Lp(a) levels, and qualitative
abnormalities might be normalized or remained unchanged
after treatment, suggesting a more complex cause of dyslipi-
demia in hypothyroidism [29, 31, 36–43].
Subclinical hypothyroidism is also associated with lipid
abnormalities, including mainly increased total and LDL
cholesterol in most [3, 28–30, 44–53] ,b u tn o ta l l[ 54–57],
studies. In contrast, HDL, triglycerides, Lp(a), apoB, and
apoA1 levels did not exhibit any diﬀerence between patients
withsubclinicalhypothyroidismandcontrolsinthemajority
[29, 44–57], but not all [33, 44–48, 50, 55, 58–61], studies.
Rondeauetal.foundthatTSHwasnegativelycorrelatedwith
HDL-C in euthyroid overweight or obese postmenopausal
women [62]. A quite recent study showed that transfer of
triglyceridestoHDLandphospholipidswaslowerinpatients
with subclinical hypothyroidism than that in controls while
transfer of free and esteriﬁed cholesterol to HDL, HDL par-
ticle size, and paraoxonase 1 activity did not exhibit any dif-
ference [63]( Table 2).
Regardingtheeﬀectsoftreatmentofsubclinicalhypothy-
roidism, the majority of studies suggest a normalization of
total and LDL cholesterol levels after thyroxine substitution
therapy [28, 30, 40–43, 48, 49, 52, 53, 64–67]. However,
there are few trials where LDL did not signiﬁcantly fall after
treatment [29, 46, 51], especially if the pretreatment TSH
levels were less than 10mIU/L [49, 68]. Triglycerides, HDL,
apoA1, apoB, and Lp(a) levels are less inﬂuenced by thy-
roxine treatment in the majority of studies in subclinical
hypothyroidism [28–30, 38, 43–49, 52, 53, 58, 65, 66]. How-
ever, few studies exist that showed improved HDL, apoA1,
apoB, and/or Lp(a) levels after treatment of subclinical
hypothyroidism [46–48, 51, 52, 58, 61, 67]. A quite recent
study showed that the reduced transfer of triglycerides to
HDL and phospholipids in subclinical hypothyroidism was




73], while only a few data support no change [21]. Lower
triglycerides, HDL, apoA1, apoB, and Lp(a) levels have beenJournal of Lipids 3
Table 2: Lipid abnormalities in clinical and subclinical thyroid disorders.
Clinical hypothyroidism Subclinical
hypothyroidism Clinical hyperthyroidism Subclinical
hyperthyroidism
Total cholesterol Increased Increased or unaltered Decreased




(rarely unaltered) Decreased or unaltered
HDL Unaltered or increased Unaltered
(rarely decreased) Unaltered or decreased Unaltered?
(a few data exist)
Lipoprotein (a) Unaltered or increased Unaltered
(rarely increased)
Decreased?
(a few data exist)
Unaltered?
(a few data exist)





(a few data exist)
Apolipoprotein B Unaltered or increased Unaltered or increased Decreased?
(a few data exist)
Unaltered?
(a few data exist)
Apolipoprotein A1 Unaltered or increased Unaltered (usually) Unaltered or decreased Unaltered?
(a few data exist)
found in patients with hyperthyroidism compared with eu-
thyroid controls, which is questionable by other reports [21–
23, 32, 68–72]( Table 2).
In hyperthyroidism, qualitative lipid changes, includ-
ing increased levels of oxidized LDL, higher contents of
thiobarbituric acid-reactive substances and dienes in LDL,
low paraoxonase activity in HDL particles, and lower LDL
content in antioxidant vitamin E and β-carotene have been
found [21, 23, 24, 35].
The impact of treatment of hyperthyroidism on the lipid
levels is not clear. Treatment with antithyroid drugs has been
associated with elevated total and LDL cholesterol levels in
some but not all studies [12, 21, 22, 68, 74–76]. Triglycerides
are not aﬀected by antithyroid treatment [21, 42, 70, 74, 76].
HDL, apoB, apoA1, Lp(a) levels have been found increased
or unchanged after treatment [21, 22, 31, 42, 70–76].
The issue of lipid abnormalities in patients with sub-
clinical hyperthyroidism has not been fully addressed. The
existing data support normal levels of total LDL and HDL
cholesterol,triglycerides, Lp(a),apoA1 and apoB whilelower
total and LDL cholesterol hav also e been reported [77, 78].
5.Thyroid Diseaseand CardiovascularRisk
Most of the existing data supporting that thyroid disease is
associated with increased cardiovascular risk which is mainly
attributed to hemodynamic alterations as well as to a high
risk of atherosclerosis [4–7].
5.1. Thyroid Disorders and Hemodynamic Changes. In hypo-
thyroidism, the main functional cardiovascular disturbances
involve decreased heart rate, elevated peripheral vascular re-
sistance, increased diastolic blood pressure and cardiac aft-
erload, reduced blood volume and cardiac preload, and di-
minished cardiac output. Impaired left ventricular systolic
contractility at least during exercise and delayed left ven-
tricular diastolic relaxation at rest and during exercise are
common in both overt and subclinical hypothyroidism. Hy-
pothyroidism is also associated with diastolic heart failure in
the elderly [4, 7].
Inhyperthyroidism,hemodynamicchangesresultmainly
from increased β1-adrenergic activity. Increased triiodothy-
ronine levels exert positive inotropic and chronotropic ef-
fects, leading to enhanced heart rate and systolic contrac-
tility and, consequently, increased cardiac output. Increased
triiodothyronine stimulates sarcoplasmic reticulum Ca-
ATPase, leading to systolic and diastolic dysfunction. More-
over,triiodothyroninereducesperipheralvascularresistance,
causing a decrease in diastolic blood pressure and cardiac
afterload,whichfurtherraisescardiacoutput.Decreasedvas-
cular resistance accounts for activation of renin-angiotensin-
aldosterone system, which increases blood volume and car-
diac preload, augmenting cardiac output even more [5, 7].
Biondi et al. found that even patients with subclinical hy-
perthyroidism had signiﬁcantly higher average heart rate,
enhanced systolic function, impaired diastolic function with
prolonged isovolumic relaxation time, and increased left
ventricular mass compared with euthyroid subjects [79].
5.2. Thyroid Disease and Atherosclerosis. As mentioned
above, thyroid disease is related to the development of dy-
slipidemiawhichisawell-knownatherogenicfactor.Dyslipi-
demia induces insulin resistance oxidative stress, via a vice-
vicious cycle [19–24, 35]. Insulin resistance, hypertension,
inﬂammation, oxidative stress, and coagulation deﬁcits are
also promoted by thyroid disease, independently of dyslipi-
demia [4–7]. The above associations support a multifactorial
originofatherosclerosisinthyroiddisease,withdyslipidemia
playing an important role [4–7].
Overt hypothyroidism has been associated with diastolic
hypertension [4, 6, 7, 80, 81] and hyperhomocysteinemia
[82–85]. Increased levels of high-sensitivity C-reactive pro-
tein and coagulation deﬁcits have been reported in pa-
tients with hypothyroidism [83, 86–88]. Higher levels of
homeostasis model assessment and lower levels of Matsuda
indexes, suggesting insulin resistance, have been found in4 Journal of Lipids
patients with overt hypothyroidism compared with euthy-
roid subjects in some [25, 26, 89, 90]b u tn o ta l l[ 91, 92]
studies. Impaired intracellular glucose catabolism and
GLUT4 translocation, decreased glycogen synthesis and glu-
cose oxidation, and altered blood ﬂow, have been proposed
as underlying mechanisms [25, 26, 90, 93, 94]. Increased
intima-media thickness of the common carotid artery has
been reported in some studies in patients with overt hy-
pothyroidism [53, 95, 96]. A higher frequency and/or se-
verity of coronary heart disease [4, 97, 98] and an increased
ischemic stroke risk [99] have been reported in patients with
overt hypothyroidism.
Subclinical hypothyroidism has been also associated with
diastolic hypertension in most but not all studies [48, 60,
89, 100–103] .Af e wb u tn o ta l ls t u d i e sh a v er e p o r t e dh y -
perhomocysteinemia [48, 83, 104–108], higher but also
normal levels of high-sensitivity C-reactive protein [56, 57,
83, 104, 107, 109–111], and possible coagulation deﬁcits
[86, 87] in patients with subclinical hypothyroidism. Higher
levels of homeostasis model assessment and lower levels of
Matsuda indexes, suggesting insulin resistance, have been
found in patients with subclinical hypothyroidism in some
but not all studies [25, 26, 89, 104, 111]. Increased intima-
media thickness of the common carotid artery has been
found in some studies in subclinical hypothyroidism [45,
53]. In the Whickham Survey, an association was found be-
tween incident coronary heart disease and related mortality
in patients with subclinical hypothyroidism over the 20yrs
of followup, which was attenuated after levothyroxine treat-
ment [112]. In support of this, 3 meta-analyses suggested
that subclinical hypothyroidism is associated with a sig-
niﬁcant risk of coronary heart disease and cardiovascular
mortality [113–115]. Another meta-analysis by Razvi et al.
showed that the incidence and prevalence of coronary heart
disease and the risk of cardiovascular mortality were higher
in subclinical hypothyroidism, in patients younger than 65
years old and more prevalent in women [116]. Subclinical
hypothyroidism has been associated with cerebral ischemia
[117]. Although Jeong et al. in a study of 382 patients with
ischemic stroke found no diﬀerence in the prevalence of
subclinical hypothyroidism (4,5%) compared to the general
population, low-normal free T4 levels in euthyroid patients
were independently associated with a higher percentage of
ischemic stroke [118]. In addition, it has been demonstrated
that patients with subclinical hypothyroidism (especially
those with TSH ≥ 10μU/mL) and acute ischemic stroke
exhibited a better level of consciousness, a milder neuro-
logical deﬁcit at presentation, and more favorable outcomes
on the 30th and 90th day compared with euthyroid patients
[119, 120]. However, Rodondi et al. found no association
between subclinical hypothyroidism and risk for stroke
[121].
On the other hand, clinical hyperthyroidism has been as-
sociated with systolic hypertension, increased pulse pressure,
and possibly hyperhomocysteinemia [6, 7, 122, 123] Addi-
tionally, patients with overt hyperthyroidism have a hyper-
coagulable state and an increased risk of thrombosis [86].
Higher levels of homeostasis model assessment and lower
levels of Matsuda indexes have been reported, suggesting
insulin resistance. [25, 27, 71, 91–93] Decreased fractional
postprandial glucose uptake in adipose tissue, increased fast-
ing lipolysis, increased interleukin 6, and tumour necrosis
factor alpha may be associated to its development [25, 93,
124, 125]. Angina pectoris is a frequent disorder, especially
in older patients with hyperthyroidism and underlying car-
diac disease, and is due to increased heart rate and con-
tractility and high myocardial oxygen demand [5]. Some
cases of patients with hyperthyroidism due to Graves’ dis-
ease presenting with coronary artery spasm have been re-
ported[126–128].Hyperthyroidismhasbeenassociatedwith
a higher risk for ischemic stroke among young adults during
a 5-year followup which was probably associated with atrial
ﬁbrillation (AF), hypercoagulability and rarely antiphospho-
lipid antibody syndrome [129–132].
Subclinical hyperthyroidism has been also associated
withhypertensioninsomebutnotallstudies[102,103,133].
Higher HOMA, lower Matsuda indexes [27], and increased
carotid intima thickness [134] have been found in patients
with subclinical hyperthyroidism. However, the association
of subclinical hyperthyroidism with coronary heart disease
risk and cardiovascular mortality is still unclear. Ochs et al.
found a possible association, while the meta-analysis by
Singhetal.foundnosigniﬁcantassociation[113,115].Jeong
et al. in a study of 382 patients with ischemic stroke found no
diﬀerence in the prevalence of subclinical hyperthyroidism
(1,6%) compared to the general population [118].
6. Conclusion
Thyroid hormones regulate the expression of enzymes in-
volved in all steps of lipid metabolism leading to the de-
velopment of qualitative and quantitative changes of lipids,
in thyroid disease. Dyslipidemia coexists with other met-
abolic abnormalities, including, hypertension, insulin resis-
tance, and oxidative stress, all of them being risk factors
for cardiovascular disease. In addition, dyslipidemia induces
insulinresistanceandoxidativestress,viaavice-viciouscycle.
The existing data support that there is an increased car-
diovascular morbidity in patients with thyroid disease and
possibly mortality which is in part mediated by the dyslipi-
demia or the dyslipidemia-induced metabolic abnormalities.
However, more studies need to be done, especially prospec-
tive,toelucidatetherealsigniﬁcanceofdyslipidemiaorother
metabolic changes to CVD morbidity and mortality in clin-
ical and, even more, in subclinical thyroid disease.
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